Aurobindo Pharma Gets USFDA EIR for Telangana Oral Unit

Aurobindo Pharma has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Telangana-based oral solid dosage manufacturing unit, marking the successful closure of a key regulatory inspection. The development is seen as a positive step for the company’s operations in the U.S. pharmaceutical market and is expected to strengthen confidence in its manufacturing and compliance standards.

The inspection was carried out at the company’s Unit-VII facility located at the Green Industrial Park in Polepally Village, Jedcherla Mandal, Telangana, from January 28 to February 10, 2026. At the end of the inspection, the USFDA had issued a Form 483 with nine observations related to manufacturing processes and quality practices.

After reviewing the company’s responses and corrective actions, the USFDA classified the facility under the Voluntary Action Indicated (VAI) category through the EIR. This means that while the regulator identified certain observations during the inspection, it did not find them serious enough to take regulatory or enforcement action. The inspection has now been officially closed.

Also Read: Biocon Biologics Receives 5 USFDA Observations in Bengaluru

The Unit-VII facility manufactures oral solid dosage products, which form an important part of the company’s global generics business. Regulatory approvals and inspection outcomes from the USFDA play a major role for Indian pharmaceutical companies, especially those with a strong presence in the U.S. generics market.

The latest update comes at a time when Indian pharmaceutical companies are facing closer scrutiny from global regulators over manufacturing quality, compliance systems, and data integrity practices. In this environment, the successful closure of a USFDA inspection is considered an important achievement for export-focused pharmaceutical companies.

Following the announcement, shares of Aurobindo Pharma gained nearly 4 percent during intraday trading on May 6, reflecting positive market sentiment around the development. Industry observers believe the inspection closure strengthens the company’s regulatory compliance profile and supports its long-term business stability in international markets.

Headquartered in Hyderabad, Aurobindo Pharma is one of India’s leading pharmaceutical exporters and supplies generic medicines and active pharmaceutical ingredients (APIs) to more than 125 countries worldwide.